- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01688791
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
9 februari 2015 uppdaterad av: Endocyte
A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers
This trial will be conducted in three parts.
Part A is a dose escalation trial followed by a dose confirmation trial in folate receptor (FR) 100% endometrial cancer participants.
The primary hypothesis of this trial is that administration of vintafolide in combination with carboplatin and paclitaxel is safe and tolerable.
Part B is a single dose, dose escalation, pharmacokinetic (PK), and QTc interval trial.
The primary objectives include determination of the maximum single tolerated dose of vintafolide and to evaluate the effect of this single maximum dose on the QTc interval.
Part C is a weekly dose escalation trial of vintafolide followed by a dose confirmation.
The primary hypothesis of this part is that weekly vintafolide has acceptable safety and tolerability in participants with advanced cancers.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
37
Fas
- Fas 1
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion criteria for all participants:
- Histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist or is unacceptable to the participant
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- At least one measurable metastatic or recurrent lesion
- No history of a previous malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or adequately treated localized prostate carcinoma; or has undergone potentially curative therapy with no evidence of disease for five years
- Adequate organ function
- Female participants of childbearing potential must be willing to use acceptable methods of birth control or abstain from heterosexual activity for the course of the study through 90 days after the last dose of study therapy
- Male participants must agree to use an adequate method of contraception for heterosexual activity starting with the first dose of study therapy through 90 days after the last dose of study therapy
Inclusion criteria for Part A:
- Tumor lesions characterized as folate receptor (FR) 100% as determined by an etarfolide Sequential Single Photon Emission Computed Tomography (SPECT) and CT scan
- Histologically-confirmed diagnosis of locally advanced or metastatic or recurrent endometrial cancer
Inclusion criteria for Parts B & C:
- Must have an etarfolatide SPECT/CT scan to determine FR status
Exclusion criteria for all participants:
- Part A & Part C if enrolled after completion of Part B: Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies) within 4 weeks prior to drug administration, or not recovered from adverse events due to agents administered more than 4 weeks earlier
- Part B: Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies) within 3 weeks prior to drug administration, or not recovered from adverse events due to agents administered more than 4 weeks earlier
- Currently participating or has participated in a study with an investigational compound or device within 28 days of initial dosing on this study
- Part A, dose escalation, Parts B and C: More than 3 prior cytotoxic regimens for metastatic disease.
- Part A, dose confirmation: Has received more than 2 prior cytotoxic regimens for metastatic disease.
- Primary central nervous system (CNS) tumor
- Active CNS metastases and/or carcinomatous meningitis.
- Known hypersensitivity to the components of the study therapy or its analogs
- Recent (i.e., ≤ 6 weeks) history of abdominal surgery or peritonitis
- Bowel occlusion or sub-occlusion
- Prior whole abdominal or whole pelvis radiation therapy or radiation therapy to >10% of the bone marrow at any time in the past or prior radiation therapy within the last 3 years to the breast / sternum, head, or neck
- Requires anti-folate therapy for the management of co-morbid conditions
- Known regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse
- Pregnant or breastfeeding or expecting to conceive, or donate sperm within the span of the study
- Human Immunodeficiency Virus (HIV)-positive
- Active Hepatitis B or C
- Symptomatic ascites or pleural effusion.
- History of stem cell or bone marrow transplant
Exclusion Criteria for Part B:
- Permanent pacemaker
- Unable to refrain from use of all concomitant medications on Day 1
- Structural heart disease, history of myocardial infarction (MI), or unstable angina
- History of cardiac arrhythmia, congestive heart failure (CHF), sick sinus syndrome, second or third degree atrioventricular (AV) block
- History of risk factors for Torsades de Pointes such as CHF, uncorrected hypokalemia, family history of long QT syndrome
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Part A: Vintafolide BIW
Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle.
Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle.
Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
|
Andra namn:
|
Experimentell: Part A: Vintafolide TIW
Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle.
Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle.
Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
|
Andra namn:
|
Experimentell: Parts B & C: Vintafolide Single Dose & Weekly (QW)
Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation.
Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
|
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Parts A and C: Number of participants with dose-limiting toxicities (DLTs)
Tidsram: Cycle 1 (21 days)
|
Cycle 1 (21 days)
|
Part B: Change from Baseline in QTc interval
Tidsram: 30 minutes pre-dose and up to 2 hours post-dose
|
30 minutes pre-dose and up to 2 hours post-dose
|
Part C: Number of Participants Experiencing an Adverse Event (AE)
Tidsram: Up to 18 weeks (six 3-week cycles)
|
Up to 18 weeks (six 3-week cycles)
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Number of participants whose best response is partial response (PR) or complete response (CR)
Tidsram: Week 6
|
Week 6
|
Progression free survival
Tidsram: Week 6
|
Week 6
|
Disease control rate
Tidsram: Week 6
|
Week 6
|
Part B: Pharmacokinetics (PK) of vintafolide, including Area Under the Curve (AUC) and Maximum Concentration (Cmax)
Tidsram: Day 1
|
Day 1
|
Part B: PK of Vintafolide Metabolites, including AUC and Cmax
Tidsram: Day 1
|
Day 1
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2012
Primärt slutförande (Faktisk)
1 september 2014
Avslutad studie (Faktisk)
1 september 2014
Studieregistreringsdatum
Först inskickad
17 september 2012
Först inskickad som uppfyllde QC-kriterierna
17 september 2012
Första postat (Uppskatta)
20 september 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
10 februari 2015
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
9 februari 2015
Senast verifierad
1 februari 2015
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 8109-001
- 2012-002799-14 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Avancerad cancer
-
TakedaAvslutad
-
TJ Biopharma Co., Ltd.Avslutad
-
Millennium Pharmaceuticals, Inc.Avslutad
-
Turku University HospitalTurku University of Applied SciencesAvslutadAdvanced Cardiac Life SupportFinland
-
Acibadem UniversityAvslutadAdvanced Cardiac Life SupportKalkon
-
Providence Health & ServicesTillgängligtKRAS G12V Mutant Advanced Epitelial Cancer
-
Acibadem UniversityRekryteringArtificiell intelligens | Advanced Cardiac Life SupportKalkon
-
Novartis PharmaceuticalsAvslutadcMET Dysegulation Advanced solida tumörerÖsterrike, Danmark, Sverige, Storbritannien, Spanien, Tyskland, Nederländerna, Förenta staterna
-
Derince Training and Research HospitalOkändIntubation, Intratrakeal | Advanced Cardiac Life Support
-
Acibadem UniversityRekryteringVirtuell verklighet | Seriöst spel | Advanced Cardiac Life SupportKalkon
Kliniska prövningar på Karboplatin
-
Samyang Biopharmaceuticals CorporationAvslutad
-
AkesoRekryteringAvancerad skivepitelcancer, icke-småcellig lungcancerKina
-
Samyang Biopharmaceuticals CorporationAvslutad
-
Myrexis Inc.OkändGlioblastoma MultiformeFörenta staterna
-
The First Affiliated Hospital of Guangzhou Medical...Okänd
-
Gynecologic Oncology Trial & Investigation ConsortiumJapanese Gynecologic Oncology GroupAvslutadÄggledarcancer | Epitelial äggstockscancer | Primärt peritonealt karcinomJapan, Förenta staterna, Hong Kong, Korea, Republiken av, Nya Zeeland, Singapore
-
Rennes University HospitalAvslutadÄggstockscancerFrankrike
-
National Cancer Institute (NCI)AvslutadBröstcancer | ÄggstockscancerFörenta staterna
-
Konstantin DragnevAbbottAvslutadLungcancer | Icke småcellig lungcancerFörenta staterna
-
Sharon SteinMerck Sharp & Dohme LLCAvslutad